Humacyte (HUMA) Enterprise Value (2020 - 2026)
Humacyte (HUMA) posted quarterly Enterprise Value of -$48.5 million for Q1 2026, up 22.77% year-over-year from -$39.5 million in Q1 2025, and up 3.88% quarter-over-quarter from -$50.5 million in Q4 2025.
Humacyte (HUMA) Enterprise Value (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Enterprise Value for 7 consecutive years, with -$48.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 22.77% year-over-year to -$48.5 million; the TTM figure through Mar 2026 stood at -$48.5 million (up 22.77% YoY), while the FY2025 annual figure was -$50.5 million, down 12.37% from the prior year.
- Enterprise Value grew to -$48.5 million in Q1 2026 per HUMA's latest filing, from -$50.5 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$19.5 million in Q3 2025 and bottomed at -$206.2 million in Q1 2022.
- Historically, Enterprise Value has averaged -$96.4 million across 5 years, with a median of -$93.6 million in 2024.
- Annual changes were most pronounced in 2022 — Enterprise Value plunged 49204.9% — and 2024, when it soared 79.43%.
- Humacyte's Enterprise Value stood at -$151.9 million in 2022, then surged by 47.03% to -$80.4 million in 2023, then jumped by 44.14% to -$44.9 million in 2024, then slipped by 12.37% to -$50.5 million in 2025, then increased by 3.88% to -$48.5 million in 2026.
- Business Quant data shows HUMA's Enterprise Value at -$48.5 million in Q1 2026, -$50.5 million in Q4 2025, and -$19.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Humacyte | 158.12 Mn | 158.12 Mn | -825,000.00 | -79.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -79.90 Mn |
| Mar 31, 2026 | -48.54 Mn |
| Dec 31, 2025 | -50.50 Mn |
| Sep 30, 2025 | -19.49 Mn |
| Jun 30, 2025 | -38.00 Mn |
| Mar 31, 2025 | -62.85 Mn |
| Dec 31, 2024 | -44.94 Mn |
| Sep 30, 2024 | -20.57 Mn |
| Jun 30, 2024 | -93.56 Mn |
| Mar 31, 2024 | -115.50 Mn |
| Dec 31, 2023 | -80.45 Mn |
| Sep 30, 2023 | -100.00 Mn |
| Jun 30, 2023 | -114.60 Mn |
| Mar 31, 2023 | -131.68 Mn |
| Dec 31, 2022 | -151.88 Mn |
| Sep 30, 2022 | -171.73 Mn |
| Jun 30, 2022 | -189.04 Mn |
| Mar 31, 2022 | -206.22 Mn |
| Dec 31, 2021 | -225.50 Mn |
| Sep 30, 2021 | -240.40 Mn |